Navigation Links
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
Date:4/21/2009

ucts include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access recently announced the acquisition of MacroChem Corporation. This acquisition provides Access with three additional late-stage product candidates. Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, has already completed two Phase 3 trials. EcoNail is a topically applied econazole lacquer based on Access' proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue a
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. New organic material may speed Internet access
3. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
6. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014 TransVac Solutions, the trusted leader ... transport solutions for hospitals, will be exhibiting at booth ... Annual Conference & Technical Exhibition Aug. 3-6 in Chicago, ... for making hospitals cleaner, reducing infection risk and saving ... life cycle. Staff will be available at booth ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)... 29, 2014 G-CON Manufacturing Inc., the ... today announced a new leadership appointment designed to drive ... and abroad. , Maik Jornitz, Chief Operating Officer ... President charged with leading the pioneering company through its ... this stage of development and look forward to providing ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... May 22 Advance Nanotech, Inc., (OTC,Bulletin Board: AVNA), ... selected as one of four finalists for the 2008 ... for,innovation in engineering. HRH the Duke of Edinburgh will ... medal to the winner of this year,s,competition at the ...
... Inc. (Nasdaq and SWX: BMRN) will host a ... Thursday, June 5, 2008 from,7:30 a.m. to 11:30 ... New York City. Members,of BioMarin,s senior management team ... new information about advancements in the,research and development ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... REOLYSIN(R) at the 40-litre,batch size to SAFC ... the successful scale-up from 20 litres to ... Yields at the 40-litre scale should ...
Cached Biology Technology:Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 2Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 3Advance Nanotech's Owlstone Subsidiary Selected as One of Four Finalists in The 2008 Royal Academy of Engineering MacRobert Awards Competition 4BioMarin to Host Research and Development Day June 5th 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3
(Date:7/29/2014)... Maryland Schools of Dentistry (UM SOD) and Medicine ... received a five-year $10.7 million grant award from ... (NIAID) of the National Institutes of Health to ... diseases (STDs). The grant, which renews a previous ... new direction for the research by studying chlamydial ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
... with Sartorius Stedim Biotech (SSB) and Adolf Kühner AG ... 2009 , ,Monthey, 19. Mai 2009 / b3c ... contract manufacturing to the biopharmaceutical industry, expands its product ... bioreactor. OrbShake bioreactors rely on orbital shaking ...
... plants into a renewable, nonpolluting replacement for crude oil. ... convert plant biomass into a building block for plastics ... have successfully converted cellulose -- the most common plant ... in one step. The result builds upon ...
... recently awarded 13 grants totaling more than $191,000 ... Grant proposals were reviewed during SIR,s 34th Annual ... Foundation is proud to be able to contribute ... SIR Foundation grant program is designed to benefit ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3Plastic that grows on trees, part two 2Society of Interventional Radiology Foundation awards $191,000 in grants 2Society of Interventional Radiology Foundation awards $191,000 in grants 3